{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:41:04Z","timestamp":1784673664449,"version":"3.55.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Left ventricular hypertrophy and asymmetric dimethylarginine (ADMA) are surrogate markers of cardiovascular disease (CVD) in the dialysis population. This study aimed to evaluate the effect of a calcium channel blocker-based antihypertensive regimen compared to a beta-blocker-based antihypertensive regimen on left ventricular mass index (LVMI) and ADMA levels in hypertensive patients on hemodialysis (HD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This was a parallel-design, open-label, single-center randomized controlled trial on 46 hypertensive patients on maintenance HD, with no history of CVD. Patients were randomly assigned to receive amlodipine 10\u200amg\/d (n\u200a=\u200a23) or bisoprolol 10\u200amg\/d (n\u200a=\u200a23). Office-based blood pressure (BP) was targeted to \u2264 140\/ 90\u200amm Hg. The outcome was the change in LVMI and ADMA from baseline to 6\u200amonths.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Baseline demographic and clinical characteristics did not vary between groups. After 6\u200amonths of treatment, amlodipine-based therapy induced a greater reduction in LVMI from baseline than bisoprolol-based treatment (35\u200a\u00b1\u200a34.2 vs 9.8\u200a\u00b1\u200a35.9\u200agm\/m<jats:sup>2<\/jats:sup>; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.017). A similar reduction in the mean BP occurred with treatment in both groups. ADMA concentration decreased significantly from baseline in the amlodipine group (0.75\u200a\u00b1\u200a0.73 to 0.65\u200a\u00b1\u200a0.67\u200anmol\/mL; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.001), but increased nonsignificantly in the bisoprolol group (0.64\u200a\u00b1\u200a0.61 to 0.78\u200a\u00b1\u200a0.64\u200anmol\/mL; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.052).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This study showed that compared to a bisoprolol-based regimen, an amlodipine-based antihypertensive regimen resulted in a significantly greater reduction in LVMI and ADMA levels from baseline in hypertensive patients on HD despite similar BP reduction in both groups. These findings support the re-evaluation of amlodipine as a potential first-line antihypertensive treatment in patients on HD without previous CVD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial Registration:<\/jats:title>\n            <jats:p>Clinicaltrials.gov Identifier: NCT04085562, registered September 2019.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028322","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T19:27:47Z","timestamp":1640287667000},"page":"e28322","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Effect of amlodipine versus bisoprolol in hypertensive patients on maintenance hemodialysis"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1990-1530","authenticated-orcid":false,"given":"Ahmed Mohamed","family":"Youssef","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham Abdallah","family":"Elghoneimy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nephrology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged Wasfy","family":"Helmy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Mokhtar","family":"Abdelazeem","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cardiology and Angiology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha Mahmoud","family":"El-Khodary","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrneph.2016.129","article-title":"Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis","volume":"12","author":"Georgianos","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1097\/01.ASN.0000019641.41496.1E","article-title":"Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study","volume":"13","author":"Longenecker","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11906-010-0137-z","article-title":"Should all hypertensive dialysis patients receive a blocker of the renin-angiotensin system?","volume":"12","author":"Sinha","year":"2010","journal-title":"Curr Hypertens Rep"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/HYPERTENSIONAHA.108.128116","article-title":"Cardiovascular protection with antihypertensive drugs in dialysis patients","volume":"53","author":"Agarwal","year":"2009","journal-title":"Hypertension"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0140-6736(09)60212-9","article-title":"Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials","volume":"373","author":"Heerspink","year":"2009","journal-title":"Lancet"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/ki.1989.192","article-title":"Impact of left ventricular hypertrophy on survival in end-stage renal disease","volume":"36","author":"Silberberg","year":"1989","journal-title":"Kidney Int"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1523-1755.2004.00530.x","article-title":"Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression","volume":"65","author":"Zoccali","year":"2004","journal-title":"Kidney Int"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1523-1755.2000.00161.x","article-title":"Inadequate diagnosis and therapy of arterial hypertension as causes of left ventricular hypertrophy in uremic dialysis patients","volume":"58","author":"Cannella","year":"2000","journal-title":"Kidney Int"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0272-6386(96)90357-1","article-title":"Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention","volume":"27","author":"Levin","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1681\/ASN.V12122759","article-title":"Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study","volume":"12","author":"London","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000049060","article-title":"Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease","volume":"90","author":"Shibasaki","year":"2002","journal-title":"Nephron"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3109\/0886022X.2010.502276","article-title":"Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"32","author":"Yilmaz","year":"2010","journal-title":"Ren Fail"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ndt\/13.3.564","article-title":"Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)","volume":"13","author":"Schmieder","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.109.136655","article-title":"Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies","volume":"54","author":"Fagard","year":"2009","journal-title":"Hypertension"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(01)07217-8","article-title":"Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study","volume":"358","author":"Zoccali","year":"2001","journal-title":"Lancet (London, England)"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1567-5688(03)00030-8","article-title":"ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease","volume":"4","author":"B\u00f6ger","year":"2003","journal-title":"Atheroscler Suppl"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1523-1755.2002.00437.x","article-title":"Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients","volume":"62","author":"Zoccali","year":"2002","journal-title":"Kidney Int"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1038\/sj.ki.5001983","article-title":"Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis","volume":"70","author":"Aslam","year":"2006","journal-title":"Kidney Int"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standards committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiograph","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/01.ASN.0000117977.14912.91","article-title":"Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients","volume":"15","author":"Zoccali","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1161\/01.CIR.82.1.105","article-title":"Salt and water retention and calcium blockade in uremia","volume":"82","author":"London","year":"1990","journal-title":"Circulation"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/ndt\/gfn304","article-title":"Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients","volume":"23","author":"Tepel","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1161\/01.CIR.90.6.2786","article-title":"Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: Comparative effects of ACE inhibition and calcium channel blockade","volume":"90","author":"London","year":"1994","journal-title":"Circulation"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/nep.12362","article-title":"The rationale and design of the beta-blocker to lower cardiovascular dialysis events (BLOCADE) feasibility study","volume":"20","author":"Roberts","year":"2015","journal-title":"Nephrology"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/0002-9149(92)91192-7","article-title":"Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine","volume":"70","author":"Schulte","year":"1992","journal-title":"Am J Cardiol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/ndt\/12.7.1441","article-title":"Blood pressure independent effects of nitrendipine on cardiac structure in patients after renal transplantation","volume":"12","author":"Rockstroh","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/0022-2828(95)90042-X","article-title":"The effects of modulation of calcium influx through the voltage-sensitive calcium channel on cardiomyocyte hypertrophy","volume":"27","author":"Lubic","year":"1995","journal-title":"J Mol Cell Cardiol"},{"issue":"(Supplement 2)","key":"R32-20250504","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1097\/00005344-199117002-00023","article-title":"Role of intracellular cation abnormalities in development of left ventricular hypertrophy","volume":"17","author":"Inoue","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1161\/01.HYP.29.3.715","article-title":"The cardiac \u03b2-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease","volume":"29","author":"Castellano","year":"1997","journal-title":"Hypertension"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1592\/phco.27.9.1322","article-title":"Discordant effects of \u03b2-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff","volume":"27","author":"Epstein","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000110092","article-title":"Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review","volume":"28","author":"Jacobi","year":"2008","journal-title":"Am J Nephrol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1253\/jcj.65.775","article-title":"Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension","volume":"65","author":"Ito","year":"2001","journal-title":"Jpn Circ J"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jash.2010.11.003","article-title":"The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension","volume":"5","author":"Kandavar","year":"2011","journal-title":"J Am Soc Hypertens"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:08:00Z","timestamp":1746338880000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028322"}},"subtitle":["A randomized controlled trial"],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":38,"journal-issue":{"issue":"51","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028322","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"assertion":[{"value":"2021-07-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}